Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study
- Totality of data supports potential for ST-920 as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care
- ST-920 has potential as a one-time, durable treatment option for Fabry disease that can improve patient outcomes